高级检索
当前位置: 首页 > 详情页

ENKUR recruits FBXW7 to ubiquitinate and degrade MYH9 and further suppress MYH9-induced deubiquitination of β-catenin to block gastric cancer metastasis

文献详情

资源类型:
Pubmed体系:
机构: [1]Cancer Center, Integrated Hospital of Traditional Chinese Medicine Southern Medical University Guangzhou P. R. China. [2]Department of Gastroenterology Hunan People's Hospital Changsha P.R. China. [3]School of Pharmacy Guangdong Medical University Dongguan P.R. China. [4]School of Public Health University of South China Hengyang P. R. China. [5]Oncology Department Nanfang Hospital Southern Medical University Guangzhou P.R. China. [6]Key Laboratory of Protein Modification and Degradation Basic School of Guangzhou Medical University Guangzhou P. R. China.
出处:

关键词: cell metastasis ENKUR gastric cancer MYH9

摘要:
ENKUR was shown as a suppressor in some tumors. However, the biological role of ENKUR on gastric cancer (GC) and its related molecular mechanisms is not clear. Here, we first observed that ENKUR significantly inhibited cell migration, invasion, and metastasis in GC. The molecular basis showed β-catenin-mediated epithelial-mesenchymal transition (EMT) signaling was inactivated in ENKUR-overexpressing GC cells. In addition, ENKUR knockdown markedly restored cell migration and invasion. Subsequently, ENKUR bound to MYH9 and decreased its protein expression by recruiting E3 ubiquitin ligase FBXW7 to form an ubiquitinated degradation complex. The downregulated MYH9 protein weakened the recruitment of the deubiquitinase USP2 and thus promoted the degradation of β-catenin protein, which finally suppressed EMT signaling. Finally, the oncogenic transcription factor c-Jun bound to ENKUR promoter and reduced its expression in GC. In clinical samples, decreased ENKUR expression promoted the unfavorable prognosis of GC. Our data proved the vital role of ENKUR on suppressing cell migration, invasion, and metastasis and demonstrated its potential as a therapeutic target for GC.© 2022 The Authors. MedComm published by Sichuan International Medical Exchange & Promotion Association (SCIMEA) and John Wiley & Sons Australia, Ltd.

基金:
语种:
PubmedID:
中科院(CAS)分区:
出版当年[2021]版:
最新[2025]版:
大类 | 1 区 医学
小类 | 1 区 医学:研究与实验
第一作者:
第一作者机构: [1]Cancer Center, Integrated Hospital of Traditional Chinese Medicine Southern Medical University Guangzhou P. R. China.
共同第一作者:
通讯作者:
通讯机构: [1]Cancer Center, Integrated Hospital of Traditional Chinese Medicine Southern Medical University Guangzhou P. R. China. [6]Key Laboratory of Protein Modification and Degradation Basic School of Guangzhou Medical University Guangzhou P. R. China. [*1]Cancer Center, Integrated Hospital of Traditional Chinese Medicine, Southern Medical University, Guangzhou, Guangdong, P. R. China.
推荐引用方式(GB/T 7714):
APA:
MLA:

资源点击量:2018 今日访问量:0 总访问量:645 更新日期:2024-07-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 广东省中医院 技术支持:重庆聚合科技有限公司 地址:广州市越秀区大德路111号